Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

EXACT SCIENCES CORPORATION

(EXAS)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Exact Sciences : Presentation

11/30/2021 | 04:31pm EST

Our mission: eradicate cancer and the suffering it causes

Evercore ISI HealthCONx conference

Kevin Conroy, Chairman and CEO

November 30, 2021

EXACT SCIENCES

1

Safe harbor statement

Forward-Looking Statements

Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management's current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission. Specifically, the Company's most recent annual report on Form 10-K and any subsequently filed quarterly reports on Form 10-Q and current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company's projections of forward-looking statements.

EXACT SCIENCES

2

EXACT SCIENCES

Detecting cancer earlier at every step, starting with screening

Diagnosis

Recurrence

Relapse

Tumor burden

Hereditary cancer/

Prognosis/

Minimal

Recurrence

Therapy

Screening

Therapy selection

residual disease

monitoring

selection

EXACT SCIENCES

3

We plan to lead 3 of the largest impact opportunities in cancer diagnostics

$25B

$18B

$15B

multi-cancer early detection

colorectal cancer screening

minimal residual disease

and recurrence monitoring

2.0

colon cancer blood test

T

TARDIS

Notes: Cologuard 2.0 and colon cancer blood test have not been cleared or approved by the FDA; U.S. TAMs only

Source: Exact Sciences estimates, includes U.S. markets only

EXACT SCIENCES

4

Supporting new innovative tests with rigorous scientific evidence

expected data readouts

U.S. TAM

current evidence

1H 2022

2H 2022

1H 2023

Cologuard 2.0

$18B

colon blood

multi-cancer

$25B

minimal residual

$15B

disease

case-control

prospective

Note: these tests have not been cleared or approved by the FDA; Cologuard 2.0 and colon blood prospective data may not read out simultaneously

Sources: https://www.exactsciences.com/publications

EXACT SCIENCES

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

EXACT Sciences Corporation published this content on 30 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 November 2021 21:30:18 UTC.


ę Publicnow 2021
All news about EXACT SCIENCES CORPORATION
01/10Exact Sciences' Q4 Revenue Outlook Beats Estimates But Caution Warranted on Screening B..
MT
01/10EXACT SCIENCES : Announces Preliminary Fourth Quarter 2021 Results - Form 8-K
PU
01/10Exact Sciences Provides Q4, Full-Year 2021 Revenue Guidance
MT
01/10Exact Sciences Acquires PreventionGenetics for $190 Million in Cash, Stock
MT
01/10Exact Sciences Corporation Reports Preliminary Unaudited Revenue Guidance for the Fourt..
CI
01/10Exact Sciences Corp. and OncXerna Therapeutics, Inc. Announce Licensing Agreement to He..
CI
01/09Exact Sciences and OncXerna Announce Licensing Agreement to Help Predict Immunotherapy ..
PR
01/09Exact Sciences Acquires PreventionGenetics to Accelerate Availability of Hereditary Can..
PR
01/09Exact Sciences Corporation acquired PreventionGenetics LLC for $190 million.
CI
01/03EXACT SCIENCES : Madison School Nurses Tour COVID-19 Lab
PU
More news
Analyst Recommendations on EXACT SCIENCES CORPORATION
More recommendations
Financials (USD)
Sales 2021 1 751 M - -
Net income 2021 -515 M - -
Net Debt 2021 1 330 M - -
P/E ratio 2021 -26,0x
Yield 2021 -
Capitalization 13 515 M 13 515 M -
EV / Sales 2021 8,48x
EV / Sales 2022 7,56x
Nbr of Employees 4 900
Free-Float -
Chart EXACT SCIENCES CORPORATION
Duration : Period :
Exact Sciences Corporation Technical Analysis Chart | EXAS | US30063P1057 | MarketScreener
Technical analysis trends EXACT SCIENCES CORPORATION
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 18
Last Close Price 78,43 $
Average target price 126,71 $
Spread / Average Target 61,6%
EPS Revisions
Managers and Directors
Kevin T. Conroy Chairman, President & Chief Executive Officer
Jeffrey Thomas Elliott Executive VP, Chief Operating & Financial Officer
Graham Peter Lidgard Chief Science Officer, SVP-Research & Development
Sandra Statz Senior VP-Clinical & Regulatory Affairs
Gary Frings Chief Information Officer
Sector and Competitors